header logo image


Page 35«..1020..34353637..4050..»

Archive for the ‘Biotechnology’ Category

Viewpoint: Biotechnology could save our favorite banana. Will anti-GMO activists stand in the way? – Genetic Literacy Project

Saturday, February 8th, 2020

In 1923,Frank Silver and Irving Cohn publisheda song that became a major hitfor the Billy Jones Orchestra, with thesignature line Yes, we have no bananas; we have no bananas today. It turned out to be sadly prophetic as, in the 1950s, the banana trees that supplied the entire global banana export business were wiped out by a soil-borne fungal diseaseknown asPanama Wilt.

The industry at that time was almost entirely based on a single banana cultivar called Gros Michel (meaning Big Mike), and it was susceptible to infection by a strain of fungus called Fusarium. Once the soil of a given plantation was contaminated with that strain, any Gros Michel tree grown there would soon die.

By good fortune, a different banana cultivar that was being grown in the South Seas was able to substitute for Gros Michel as a commercial line, and this new Cavendish cultivar became the new banana of international commerce, as it remains to this day. (Check out this interesting blog post about the history of the Cavendish variety and how it actually passed through a greenhouse in England in that process! And here is another good post about the history of this disease and the industry.)

Unfortunately, its about time for some band to cover Yes, We Have No Bananas because, evolution being what it is, a new strain of Fusarium Tropical Race 4 has arisen and it is lethal to the Cavendish. The disease is slowly making its way around the world, and since it can be spread in a particle of dirt on something like a boot, it will almost inevitably make it to the Central and South American growing regions that supply both North America and Europe with their bananas.

Although this unfortunate scenario has been on the minds of the banana industry for decades, it is now starting to get more attention in the mainstream press. One part of the story that has been shocking to these outside observers is that such a huge industry would ever be dependent on a single cultivar of banana. As Stephen Mihm put it for Bloomberg, this looming bananapocalypse is attributable to a vulnerability that comes from the practice of extreme monoculture.

While I understand why observers might be shocked that a nearly $12 billion industry depends almost exclusively on the Cavendish banana, I do want to push back on the implied conclusion that this represents some sort of irrational or irresponsible expression of big ag or whatever other demons are imagined by the Food Movement.

When you see something that is a standard practice in a very large, nationally diverse and multi-company business like bananas, I would suggest that it is appropriate to ask not what is wrong with this system but rather, What are the practical factors that drive this seemingly irrational practice?

Im not a banana expert, but in the mid-1990s, two of my first jobs as an independent consultant had to do with the banana industry. It was during the exciting early years of commercial plant biotechnology, and many industries were asking, What might this new technology do for our business? Both of my projects involved early-stage discussions between a major banana company and a plant biotech company four different entities in all. These were drawing board stage projects, with the goal of figuring out if certain ideas could ever make economic sense: Would they be something worth years of effort and millions of dollars for research?Still, overall, biotechnology looked like a way for this industry to tap into genetic diversity.

The fun part for me was getting to do a deep dive into the details of how bananas are grown, handled, shipped and marketed. I got to travel to Honduras, Costa Rica and Ecuador to tour banana plantations and interact with experts at the major banana export companies. As I said, Im not an industry insider, but I think I can shed some light on why there are not more kinds of bananas grown for export.

As modern consumers, we are offered an amazingly diverse selection of fresh fruits and vegetables year-round, so it is important to think back to the early days of this offer of plenty. Having grownup in Denver in the 1960s, I can recall that, except for a few summer months, almost the only fresh fruit options at the grocery store were bananas, apples and oranges. I have a podcast aboutwhy apples were ever on that list. But if you think about it, the very fact that we can so easily enjoy fresh bananas in temperate regionsis a bit remarkable.

Bananas can grow only in regions where there is never frost, and they do best in truly tropical climates. How did a tropical fruit become a mainstream, reasonably priced, healthful, kid-popular fruit for people who experience winter?

In tropical regions, there is a great deal of genetic diversity among wild bananas and considerable diversity among the banana or plantain types that humans cultivate. However, very few of these bananas could ever meet the criteria needed to be a viable export crop.

First of all, a banana for export has to be seedless. Many wild bananas have large, very hard black seeds not something that has much consumer appeal. The bananas that people like are seedless because they have triploid genetics three of each chromosome vs. the two that we have. That is the same way we get seedless watermelons, grapes, etc. Its not some GMO thing; it happens at times in the plant kingdom, and we humans like it! Still, improving or changing the cultivar through conventional breeding isnt an option if it makes no seeds.

Next, the banana needs to be productive in terms of overall yield per tree or acre. Im sure no one in the 1920s was calculating it, but in modern sustainability thinking, the land-use efficiency of a crop is an important criterion. That, along with water-use efficiency, small carbon footprint and energy footprint,is all very much tied to good yield. The usable per-hectare yields of the Cavendish variety are quite high, and that is why it has been a both economically viable and environmentally sustainable choice for a long time.

But probably the most limiting requirement for a banana variety to be commercially acceptable is thatit has to be shippable. In the modern era, we have lots of transport options for food products, but during the era when the banana was becoming an item of international trade, the only viable option was ocean shipping. A product being moved from the tropics to North America or Europe needed a very-low-cost transport option if it was ever going to be a mainstream consumer product. Most fresh produce products loaded onto a ship for a two-plus-week trip to a northern port would be a soup of decay by the time they arrived.

What made the Gros Michel and its successor, the Cavendish, remarkable was that they could make that trip at a temperature range of 55-58 degrees Fahrenheit, and so not even require lots of energy for refrigeration. Very few of the wonderful range of cultivated or wild banana types could ever do that, but because the Cavendish can be shipped this way, the energy and carbon footprint ofits shipment is small. This crop has a very attractive food-miles profile.

In addition,it turns out that the conditions under which bananas grow can affect their shipping potential. There is a disease that infects only the leaves of banana plants called Black Sigatoka. If a banana tree has suffered too much of that infection, even the robust Cavendish variety wont be able to make the trip by sea. One thing I learned on my tour was that plantations have employees whose whole job is to survey the plantation on a tree-by-tree basis in order to qualify the fruit for shipment based on how well that disease has been managed.

But it gets even more complicated than that (heres a good video summary of the process). Bananas are picked in Central and South America at a green stage imagine a fruit more completely green than the greenest one youve ever seen in the clusters in your store. When they get to their destination, they are put into ripening rooms, where they are exposed to ethylene gas to start them on the way to the ripe yellow fruit you know. Before you freak out, know that ethylene is the fully natural plant hormone that induces ripening in most fruits and vegetables.

There is a definite art to this ripening process, and highly valued experts who can assess each shipment of bananas know just how to handle them in the ripening rooms to achieve the goal of delivering just right bananas at retail. This process has to factor in issues like ups and downs in demand and turnover rates at key retail customer outlets, in addition to the condition of the incoming fruit.

I know that at the stores where I shop, I can consistently buy bananas that are close to ripe but not fully, such that I can hope to consume them all before they turn black. We consumers might think we have a balancing act to do when it comes to timing ripening and consumption of the bananas from our counters, but imagine that on a huge scale for the banana distribution chain.

There is one more critical element of the business model: Those ships that come to our ports loaded with bananas certainly cant go back empty. The banana shipping companies are also seriously involved in their back-haul business of bringing back products of interest in the source countries. Having a well-understood, predictable crop helps with running that business efficiently as well.

So for the international banana business to work in a way that provides a relatively low-cost product acceptable to consumers, it needs to be able to function in a reliable and predictable fashion. Figuring out how to do this with a new banana variety would be a huge challenge. How do you grow it efficiently? Can the crop make the trip reliably? How can its ripeness be managed in order to meet both the distribution chain requirements and the needs of consumers for decent counter life? Will all of this work in a way that is compatible with a viable back-haul business?

So while it is easy to think that the banana industry is crazy to depend on one cultivar, Isubmit to you thatit is not without reasonand it implies noirresponsibility.

So does that just mean that we are inevitably going to live out the unintended prophecy of yes, we have no bananas? I think that depends on whether we continue to live in a world where anti-biotechnology groups are able to exercise the control that they currently have over our food system.

Let me explain. Remember that my introduction to bananas was based on excitement about what biotechnology could do for the crop. One of the concepts was to develop bananas that were resistant to that leaf infection disease that can compromise ship-ability. Control of that disease requires something like 40 fungicide sprays a year, so as you can imagine, there would be a huge cost savings if the trees could be made resistant.

The other concept on the table was modifying the banana so that it would stay in that nice yellow, but not yet black, stage longer on the consumers counter. Ill never forget that in the first meeting about that idea, a participant who worked for a UK-based banana importer said in his very British accent: Why would you want to do that? Dont you know that the dustbin is a major consumer of bananas? Obviously, he wasnt attuned to current sensitivity to the need for food waste reduction. I thought it was cool that a banana company was serious about an idea that might reduce food waste, with the hope that it would make consumers more comfortable about buying even more bananas.

Well, these were just theoretical ideas at the time, and they didnt go anywhere because it soon became evident that the anti-GMO forces were quite successful at putting brand-sensitive companies in an untenable spot if they were using GMO crops not just for generic ingredients but for brand-central crops.A dramatic examplewas how fast-food chains like McDonalds moved to avoid biotech potatoes for their signature fries.

It quickly became clear to the banana companies that their brands and their retail store access could be compromised if they pursued GMO options. The irony here is that this would have been the most viable strategy with which to bring genetic diversity into the logical but extreme monoculture of bananas.

Sothe irony is that if the yes, we have no bananas scenario becomes a reality, it will be because we as a global society didnt use a safe, viable, scientifically sound strategy torationally deal with the problem in the banana crop.

Public institution scientists in Australiaand entrepreneurial scientists in Latin America have come up with ways to modify commercially relevant bananas to resist the Fusarium disease. Ideally, there would be the potential to use several approaches, either in the same banana or in different fields; that wouldavoid delay selection for resistance and avoid yet another dependency on a single line. It is likely that the heritage variety Gros Michel could be made commercially viable once again!

If the Fusarium-resistant biotech bananas were introduced, activists would almost certainly attack them as GMO.Would any of the big banana companies have the guts to move forward with the technology in spite of the inevitable brand attacks by NGOs?Would any big food retailers be willing to resist the inevitable pressures not to stock that fruit? That retail blockage strategy is being used today against other new biotech offerings such asnon-browning applesandpotatoesandfast-growing, terrestrially raised salmon.

At one level, this is a question about what will be available for us as consumers. Will we continue to have this highly consumed, reasonably priced, child-friendly, healthy food option? Maybe not. But there is another big question.

One thing I witnessed on those visits to the banana industry back in the 90s was that large communities in Central and South America flourish because of the jobs that this industry creates. We in the rich world will still have lots of other fruit choices if the stores have no bananas, but that flexibility isnt there for the familiesthat have been doing the work to provide us with this staple food option for so many decades.

I would think that most activists are the kind of people who care about the availability of healthy, low-cost fruit options; I doubt that they would want to see the banana-producing communities impoverished. However, if the current paradigm of anti-GMO intimidation of fruit companies and retailers continues, that is where we are headed.

A version of this story originally ran on the GLP on April 16, 2018.

Steve Savage is a plant pathologist and senior contributor to the GLP. His Pop Agriculture podcast is available for listening or subscription on iTunes and Google Podcasts. Follow him on Twitter @grapedoc

Go here to read the rest:
Viewpoint: Biotechnology could save our favorite banana. Will anti-GMO activists stand in the way? - Genetic Literacy Project

Read More...

Researchers identify roots of childhood asthma – European Biotechnology

Saturday, February 8th, 2020

Infants who show defective immune responses to microbial components are more likely to acquire asthma later in childhood, according to a study of 541 children.

The discovery of a team headed by Hans Bisgaard at Gentofte Hospital in Gentofte, Denmark, reveals that childhood asthma is closely intertwined with the behaviour of the immune system early in life a finding that could open the door to new diagnostics and preventative strategies.

The immune system develops as immune cells begin to respond to different types of microbes from the environment. This early stage of development is critical: any persistent abnormalities can trigger chronic inflammation and may raise the risk of asthma and other allergic diseases.

To flesh out the connection between early-life immunity and asthma, first author Anna Thysen et al. studied a longitudinal cohort of 541 children, by analysing blood samples collected at 18 months and comparing these immune profiles to clinical outcomes at six years of age. The scientists exposed blood cells gathered from the 18 month olds to different molecules from viruses, bacteria and fungi. They observed that neutrophils of the innate immune system from some infants responded too strongly to certain viruses, and these same infants were more susceptible to transient asthma as they approached the age of six. Furthermore, some infants harboured T cells that produced excessive amounts of IL-5 and IL-13 two pro-inflammatory cytokines associated with asthma and were more likely to have developed persistent asthma at six years of age.

Thysenet al.speculate that future blood tests to detect abnormal immune signatures in infants might allow for earlier prevention or treatment of childhood asthma.

See the original post:
Researchers identify roots of childhood asthma - European Biotechnology

Read More...

Industry Analysis: Should You Buy Esperion Therapeutics Inc (ESPR) in Biotechnology? – InvestorsObserver

Saturday, February 8th, 2020

The 66 rating InvestorsObserver gives to Esperion Therapeutics Inc (ESPR) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 85 percent of stocks in the Biotechnology industry, ESPRs 66 overall rating means the stock scores better than 66 percent of all stocks.

Click Here to get the full Stock Score Report on Esperion Therapeutics Inc (ESPR) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Esperion Therapeutics Inc (ESPR) stock has gained 7.95% while the S&P 500 has fallen -0.25% as of 11:33 AM on Friday, Feb 7. ESPR has gained $4.61 from the previous closing price of $57.98 on volume of 444,201 shares. Over the past year the S&P 500 is higher by 23.33% while ESPR has gained 38.57%. ESPR lost -$3.69 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

See the article here:
Industry Analysis: Should You Buy Esperion Therapeutics Inc (ESPR) in Biotechnology? - InvestorsObserver

Read More...

Read This Before Judging Avecho Biotechnology Limiteds (ASX:AVE) ROE – Simply Wall St

Saturday, February 8th, 2020

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. To keep the lesson grounded in practicality, well use ROE to better understand Avecho Biotechnology Limited (ASX:AVE).

Over the last twelve months Avecho Biotechnology has recorded a ROE of 2.5%. One way to conceptualize this, is that for each A$1 of shareholders equity it has, the company made A$0.03 in profit.

Check out our latest analysis for Avecho Biotechnology

The formula for ROE is:

Return on Equity = Net Profit (from continuing operations) Shareholders Equity

Or for Avecho Biotechnology:

2.5% = AU$158k AU$6.2m (Based on the trailing twelve months to June 2019.)

Most know that net profit is the total earnings after all expenses, but the concept of shareholders equity is a little more complicated. It is all earnings retained by the company, plus any capital paid in by shareholders. The easiest way to calculate shareholders equity is to subtract the companys total liabilities from the total assets.

Return on Equity measures a companys profitability against the profit it has kept for the business (plus any capital injections). The return is the profit over the last twelve months. A higher profit will lead to a higher ROE. So, all else being equal, a high ROE is better than a low one. That means ROE can be used to compare two businesses.

One simple way to determine if a company has a good return on equity is to compare it to the average for its industry. However, this method is only useful as a rough check, because companies do differ quite a bit within the same industry classification. As is clear from the image below, Avecho Biotechnology has a lower ROE than the average (7.7%) in the Pharmaceuticals industry.

That certainly isnt ideal. Wed prefer see an ROE above the industry average, but it might not matter if the company is undervalued. Nonetheless, it might be wise to check if insiders have been selling.

Most companies need money from somewhere to grow their profits. That cash can come from retained earnings, issuing new shares (equity), or debt. In the first two cases, the ROE will capture this use of capital to grow. In the latter case, the use of debt will improve the returns, but will not change the equity. In this manner the use of debt will boost ROE, even though the core economics of the business stay the same.

Avecho Biotechnology is free of net debt, which is a positive for shareholders. Without a doubt it has a fairly low ROE, but that isnt so bad when you consider it has no debt. At the end of the day, when a company has zero debt, it is in a better position to take future growth opportunities.

Return on equity is useful for comparing the quality of different businesses. A company that can achieve a high return on equity without debt could be considered a high quality business. If two companies have the same ROE, then I would generally prefer the one with less debt.

But when a business is high quality, the market often bids it up to a price that reflects this. It is important to consider other factors, such as future profit growth and how much investment is required going forward. Check the past profit growth by Avecho Biotechnology by looking at this visualization of past earnings, revenue and cash flow.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Read this article:
Read This Before Judging Avecho Biotechnology Limiteds (ASX:AVE) ROE - Simply Wall St

Read More...

Here’s Why Inovio Pharmaceuticals and Vir Biotechnology Shares Have Fallen Today – Motley Fool

Saturday, February 8th, 2020

What happened

Shares of Inovio Pharmaceuticals (NASDAQ:INO) and Vir Biotechnology (NASDAQ:VIR), two companies developing drugs for the coronavirus outbreak in China, are down today on word that Gilead Sciences (NASDAQ:GILD) looks to have beaten the companies to the punch, setting up a research collaboration with Chinese authorities to run a clinical trial for its antiviral medication remdesivir.

As of 1:46 p.m. EST on Monday, Inovio had fallen 14.5%, while Vir was down 16.2%.

Image source: Getty Images.

While the news that Gilead has moved first is disappointing for the biotechs, there may still be a need for Inovio's 2019-nCoV coronavirus vaccine. Remdesivir might lessen the symptoms of the virus, but it won't stop the spread of the disease in mildly symptomatic patients who aren't likely to take the drug.

Vir's antibody treatment would likely compete more directly with remdesivir since it would attack the virus directly and would likely be used to treat infected patients.

Both Inovio and Vir increased in value quite a bit in January. Vir doubled, while Inovio was up almost 40% as the 2019-nCoV coronavirus outbreak has spread and investors pinned hopes on the potential to develop drugs for the virus. With the valuations already incorporating some of the potential, it's not surprising to see a pullback on news that the opportunity might not be as large as first imagined.

The bigger issue for Inovio and Vir is how long the clinical trial process could end up taking and whether the outbreak will peter out before the companies can get their treatments to market.

Continue reading here:
Here's Why Inovio Pharmaceuticals and Vir Biotechnology Shares Have Fallen Today - Motley Fool

Read More...

Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 | Research, Opportunities, Emerging Trends, Competitive Strategies and Forecasts…

Saturday, February 8th, 2020

New Jersey, United States The report is a comprehensive research study of the global Nanoparticles in Biotechnology and Pharmaceuticals market, taking into account growth factors, recent trends, developments, opportunities and the competitive landscape. Market analysts and researchers performed an in-depth analysis of the Nanoparticles in Biotechnology and Pharmaceuticals global market using research methodologies such as PESTLE and Porters Five Forces analysis. They provided precise and reliable data on the market and useful recommendations in order to help the actors to better understand the global scenario of the present and future market. The report includes an in-depth study of potential segments, including product type, application and end user, as well as their contribution to the overall size of the market.

This report covers a comprehensive study of the data affecting the Nanoparticles in Biotechnology and Pharmaceuticals market with regard to manufacturers, suppliers, market players and customers. The report also includes an overview of technology applications and strategies used by market leaders. In addition to data compiled by type, application and region, the study includes personalized research to examine the intricacies of the global Nanoparticles in Biotechnology and Pharmaceuticals market.

Key players in global Nanoparticles in Biotechnology and Pharmaceuticals market include:

Roche, GE Healthcare, Merck, Novartis, AMAG Pharmaceuticals, Amgen, Bausch & Lomb, Biogen, Celgene, Gilead, Ipsen, Leadiant Biosciences, nanoComposix, Pacira Pharmaceuticals, Pfizer, Shire

Get Complete SWOT Analysis Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=19246&utm_source=ITN&utm_medium=003

Global Nanoparticles in Biotechnology and Pharmaceuticals Market: Research Methodology

The research methodology used by analysts play an integral role in how the publication has been prepared. Analysts have used primary and secondary research methodologies to make a comprehensive analysis. For accurate and precise analysis of the global Nanoparticles in Biotechnology and Pharmaceuticals s market, analysts have a bottom-up and top-down approaches.The main sources include interviews, surveys and observations of seasoned analysts, and secondary sources cover reputable paid sources, trade journals and databases of industry organizations. Other research methods include SWOT analysis with In-Depth Market Analysis.

Drivers & Constraints of Nanoparticles in Biotechnology and Pharmaceuticals Market:

Nanoparticles in Biotechnology and Pharmaceuticals market competitiveness is the result of the expansion technique employed by market leaders. market dynamics and trends play an important role in this growth market. This report focuses on the value chain, the trend of volume and price factors that influence the market. The growth of world population and the constant evolution of consumer demand is the main cause of the market dynamics. In addition, market restrictions and limits and strategies used by companies to overcome these limits are included in market research.

Global Nanoparticles in Biotechnology and Pharmaceuticals Market: Regional Analysis

This part of the report includes detailed information on the market in various regions. Each region offers different scope for markets because every region has a different government policies and other factors. The regions included in this report are North America, Europe, Asia Pacific, and the Middle East and Africa. Information about the different areas helps the reader to understand better the global market.

Table of Content

1 Introduction of Nanoparticles in Biotechnology and Pharmaceuticals Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Nanoparticles in Biotechnology and Pharmaceuticals Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Deployment Model

5.1 Overview

6 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Solution

6.1 Overview

7 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Vertical

7.1 Overview

8 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Nanoparticles in Biotechnology and Pharmaceuticals Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Check Complete Report For Deep SWOT Analysis Updates @ https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=ITN&utm_medium=003

Our Report offers:

About Us

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]

Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Nanoparticles in Biotechnology and Pharmaceuticals Market Analysis, Nanoparticles in Biotechnology and Pharmaceuticals Market Growth, Verified Market Research

Read the original post:
Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 | Research, Opportunities, Emerging Trends, Competitive Strategies and Forecasts...

Read More...

Red Biotechnology Market 2020 | Research, Opportunities, Emerging Trends, Competitive Strategies and Forecasts 2020-2026 – Instant Tech News

Saturday, February 8th, 2020

New Jersey, United States The report is a comprehensive research study of the global Red Biotechnology market, taking into account growth factors, recent trends, developments, opportunities and the competitive landscape. Market analysts and researchers performed an in-depth analysis of the Red Biotechnology global market using research methodologies such as PESTLE and Porters Five Forces analysis. They provided precise and reliable data on the market and useful recommendations in order to help the actors to better understand the global scenario of the present and future market. The report includes an in-depth study of potential segments, including product type, application and end user, as well as their contribution to the overall size of the market.

Red Biotechnology Market was valued at USD 314.2 Billion in 2018 and is projected to reach USD 503 Billion by 2026, growing at a CAGR of 5.7% from 2019 to 2026.

This report covers a comprehensive study of the data affecting the Red Biotechnology market with regard to manufacturers, suppliers, market players and customers. The report also includes an overview of technology applications and strategies used by market leaders. In addition to data compiled by type, application and region, the study includes personalized research to examine the intricacies of the global Red Biotechnology market.

Key players in global Red Biotechnology market include:

Amgen F. Hoffmann-La Roche, Gilead Sciences CSL, Pfizer Inc

Get Complete SWOT Analysis Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=11405&utm_source=ITN&utm_medium=005

Global Red Biotechnology Market: Research Methodology

The research methodology used by analysts play an integral role in how the publication has been prepared. Analysts have used primary and secondary research methodologies to make a comprehensive analysis. For accurate and precise analysis of the global Red Biotechnology s market, analysts have a bottom-up and top-down approaches.The main sources include interviews, surveys and observations of seasoned analysts, and secondary sources cover reputable paid sources, trade journals and databases of industry organizations. Other research methods include SWOT analysis with In-Depth Market Analysis.

Drivers & Constraints of Red Biotechnology Market :

Red Biotechnology market competitiveness is the result of the expansion technique employed by market leaders. market dynamics and trends play an important role in this growth market. This report focuses on the value chain, the trend of volume and price factors that influence the market. The growth of world population and the constant evolution of consumer demand is the main cause of the market dynamics. In addition, market restrictions and limits and strategies used by companies to overcome these limits are included in market research.

Global Red Biotechnology Market : Regional Analysis

This part of the report includes detailed information on the market in various regions. Each region offers different scope for markets because every region has a different government policies and other factors. The regions included in this report are North America, Europe, Asia Pacific, and the Middle East and Africa. Information about the different areas helps the reader to understand better the global market.

Table of Content

1 Introduction of Red Biotechnology Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Red Biotechnology Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Red Biotechnology Market , By Deployment Model

5.1 Overview

6 Red Biotechnology Market , By Solution

6.1 Overview

7 Red Biotechnology Market , By Vertical

7.1 Overview

8 Red Biotechnology Market , By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Red Biotechnology Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Check Complete Report For Deep SWOT Analysis Updates @ https://www.verifiedmarketresearch.com/product/red-biotechnology-market/?utm_source=ITN&utm_medium=005

Our Report offers:

About Us

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]iedmarketresearch.com

Red Biotechnology Market Size, Red Biotechnology Market Analysis, Red Biotechnology Market Growth, Verified Market Research

Go here to read the rest:
Red Biotechnology Market 2020 | Research, Opportunities, Emerging Trends, Competitive Strategies and Forecasts 2020-2026 - Instant Tech News

Read More...

Biotech stocks get a boost from coronavirus fears — but here’s why investors should be wary – Yahoo Finance

Saturday, February 8th, 2020

Pharmaceutical stocks, which have seen temporary spikes during the coronavirus crisis as investors bet on the possibility of a vaccine, may be getting ahead of themselves.

Markets are speculating that some products may prove instrumental in the fight against the deadly disease, which has infected thousands in China, left 200 dead and rattled global markets.

However, biotech experts say that buyers should certainly be wary of trying to trade on coronavirus fears, given that most companies lack an established track record or are simply trying to position themselves to benefit from public health crisis.

Theres two things that biotech companies, especially small ones, are always looking for: Attention and cash, Brad Loncar, a biotech investor, told Yahoo Finance on Friday.

And, sadly, a lot of them take advantage of situations...putting out a press release saying they are working on something and you see their stocks zoom, Loncar added.

To be sure, not all pharma companies are created equal. To fight the coronavirus, large cap companies like Johnson & Johnson (JNJ), AbbVie (ABBV) and Gilead Sciences (GILD) announced they were repurposing HIV, Ebola and Zika products that had been developed but are not on the market to create a vaccine. Separately, Roche is planning to disseminate testing kits for the virus.

Meanwhile, China and Hong Kongs biotech companies may hold more promise for finding a treatment or cure, amid a rise of domestic Chinese companies competing with U.S. or European brands.

A lot of people dont know theres a biotech boom happening in China today, according to Loncar, who manages a Chinese biotech exchange-traded fund. Its an example that China can rise to this call.

People wear face masks and walk at a shopping mall in Taipei, Taiwan, Friday, Jan. 31, 2020. People wear face masks as they walk through a shopping mall in Taipei, Taiwan, Friday, Jan. 31, 2020. According to the Taiwan Centers of Disease Control (CDC) Friday, the tenth case diagnosed with the new coronavirus has been confirmed in Taiwan. (AP Photo/Chiang Ying-ying)

Yet finding effective treatments and cures for the virus is easier said than done. It took five years for the first Ebola vaccine to hit the market, and the coronavirus vaccine is likely to follow the same pattern.

Barring a dramatic breakthrough, it means the sickness could rage for an extended period before a solution is found which means investors should be particularly careful about sinking money into biotech and pharma companies making big promises.

That includes stocks of smaller companies, which saw fleeting rallies last week on vaccine speculation. Inovio (INO), Moderna (MRNA), Novavax (NVAX), Meridian Biosciences (VIVO), Vir Biotechnology (VIR) and BioCryst (BCRX). Virtually all of them have pared or completely reversed the weeks initial gains.

Its important to know how big the potential universe for any vaccine is likely to be, Chris Meekins, a biotech analyst, told Yahoo Finance this week.

So companies that have a partnership with the government those would be areas that are better to invest in than companies that dont have government funding, because I dont believe theres a sustained investment, he added.

Robert W. Baird research analyst Brian Skorney told Yahoo Finance the companies who do end up making something are likely not to make any money either.

It is really unlikely that anyone is going to get paid for product that even does treat coronavirus, Skorney said. its not going to be something that companies are going to be able to generate a substantial profit, he said.

Read the original:
Biotech stocks get a boost from coronavirus fears -- but here's why investors should be wary - Yahoo Finance

Read More...

Is Halozyme Therapeutics, Inc. (HALO) Stock a Good Buy in Biotechnology – InvestorsObserver

Saturday, February 8th, 2020

Halozyme Therapeutics, Inc. (HALO) is near the top in its industry group according to InvestorsObserver. HALO gets an overall rating of 54. That means it scores higher than 54 percent of stocks. Halozyme Therapeutics, Inc. gets a 60 rank in the Biotechnology industry. Biotechnology is number 51 out of 148 industries.

Click Here to get the full Stock Score Report on Halozyme Therapeutics, Inc. (HALO) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Halozyme Therapeutics, Inc. (HALO) stock is trading at $20.83 as of 10:15 AM on Wednesday, Feb 5, a rise of $1.53, or 7.9% from the previous closing price of $19.30. The stock has traded between $20.06 and $21.28 so far today. Volume today is low. So far 663,847 shares have traded compared to average volume of 1,434,881 shares.

To see the top 5 stocks in Biotechnology click here.

Read the original post:
Is Halozyme Therapeutics, Inc. (HALO) Stock a Good Buy in Biotechnology - InvestorsObserver

Read More...

Where Is The Biotech Market Heading? – CIO Applications

Saturday, February 8th, 2020

Innovation-driven biotechnology companies are all set to generate profit in the future years by executing value-based business and marketing strategies.

FREMONT, CA: Today, the availability of a broader range of high-tech applications has contributed to transforming the biotechnology industry. From physical examinations to smartly extracting information, emerging innovations help biotechnologists explore new methods to enable market expansion. Some of such trends revolutionizing the biotechnology sphere are listed below.

Digitally Driven Research

Adopting technology-based tools and applications help the modern-day professionals tackle market challenges by delivering the quality, safety, and efficacy of biotechnology products and services. The changing biotechnology demands can be achieved by upgraded tools and applications to perform researches in an advanced and instant manner. In recent years, biotechnology companies prefer digital research infrastructure, which enables them to collaborate with different experts from numerous locations and successfully examine bio components and properties.

Commercial Value-Based Pricing

It is high time for biotechnology products and service providers to set value-based pricing arrangements. The rising commercialization has increased the revenue streams; biotechnology providers can take advantage of data analytics to track customer demands and predict future market scenarios for strategically making decisions on different product pricing before the launch. Such a pricing arrangement can frame the real-time and measurable value of the biotechnology companies while attracting more stakeholders to invest in.

Automatic Conformance to Regulations

The rapidly advancing biotechnology companies need to follow different rules and regulations for testing and trading drugs. Tech-driven operational infrastructures offer smart features like automatically upgrading operational processes according to the upgraded rules and sending alerts regarding new regulations across the organization. Technology delivers the ability to access massive information from multiple resources for performing data-driven research processes.

With technology creating brilliant business opportunities, innovative solutions for biotechnology companies help the developments in genomics, proteomics, drug discovery, and more. The increasing pace of tech interventions in the industrial ecosystem has encouraged many investors to support biotechnology companies.

Originally posted here:
Where Is The Biotech Market Heading? - CIO Applications

Read More...

Inclusive comprehension of Agricultural Biotechnology Market Addressing Structure, Scope, Potential, and Growth Prospects Till 2029 – TheLoop21

Saturday, February 8th, 2020

The Overview for Agricultural Biotechnology Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 20202029

We at MarketResearch.biz will help your business by providing the latest market reports containing all the data required to capture opportunities while increasing effectiveness. The report on Agricultural Biotechnology Market has been prepared with the help of modern analytical techniques such as SWOT Analysis and PESTLE Analysis which not only covers the technical areas but also the political and ecological factors that are affecting the market. Our report will help by providing a calculated forecast so as to make business aware of incoming possible opportunities and or problems.

Leading Market players like KWS SAAT SE & Co. KGaA, ChemChina, Limagrain, Nufarm, Marrone Bio Innovations, Performance Plants Inc., Corteva, ADAMA Ltd, MITSUI & CO., LTD, Evogene Ltd., Valent BioSciences LLC, Bayer AG. have been maintaining their position in the Global Agricultural Biotechnology market with the help of their up-to-date knowledge and readily available data to make an informed decision to effectively act on any opportunities that present itself.

***Access FREE PDF Sample Copy of the Report(Contains- Keyplayers, Growth Value, Segments, etc)! Click here***

Various classifications have been applied to the data to make it more readable to suit the eyes of a businessman. Following are some of the classifications provided in the report;

By Application:Vaccine DevelopmentTransgenic Crops and AnimalsAntibiotic DevelopmentNutritional SupplementsFlower CulturingBiofuels

By Organism Type:PlantsConventional TechniquesEstablished Genetic ModificationNew Breeding TechniquesAnimalsConventional TechniquesEstablished Genetic ModificationNew Breeding TechniquesMicrobesConventional TechniquesEstablished Genetic ModificationNew Breeding Techniques

Regional Analysis:

1. North America (United States, Canada)

2. Europe (Germany, Spain, France, UK, Russia, and Italy)

3. Asia-Pacific (China, Japan, India, Australia, and South Korea)

4. Latin America (Brazil, Mexico, etc.)

5. The Middle East and Africa (GCC and South Africa)

Available Array of Customizations:

Country-level bifurcation of data in terms of Type and Application for any specific country/countries.

Expansion of scope and data forecasts until 2029

Company Market Share for specific country/countries and regions

Customized Report Framework for Go-To-Market Strategy

Customized Report Framework for Merger & Acquisitions and Partnerships/JVs Feasibility

Customized Report Framework for New Product/Service Launch and/or Expansion

Any other Miscellaneous requirements with feasibility analysis

*****Any query?Inquire/Share Your Questions HereOr Report Customization*****

Which prime data figures are included in the report?

-Market size (Last few years, current and expected)

-Market share analysis as per different companies

-Market forecast

-Demand

-Price Analysis

-Market Contributions (Size, Share as per regional boundaries)

Who all can be benefitted out of this report?

-Market Investigators

-Teams, departments, and companies

-Competitive organizations

-Individual professionals

-Vendors, Buyers, Suppliers

What are the crucial aspects incorporated in the report?

-Industry Value Chain

-Consumption Data

-Market Size Expansion

-Key Economic Indicators

In this study, the years considered to estimate the market size of the Agricultural Biotechnology are as follows:

Base Year:2019 | Estimated Year:2020 | Forecast Year: 2020 to 2029

Factors such as industry value chain, key consumption trends, recent patterns of customer behaviors, overall spending capacity analysis, market expansion rate, etc. The report also incorporates premium quality data figures associated with financial figures of the industry including market size (in USD), expected market size growth (in percentage), sales data, revenue figures and more. This might enable readers to reach quicker decisions with data and insights at hand.

The report caters to the subsequent questions pertaining To the Agricultural Biotechnology market:

Which Regional market is very likely to witness the maximum growth in terms of talk and value?

What Are the latest trends in the sector that is Agricultural Biotechnology?

What Is the forecasted value of this Agricultural Biotechnology economy in 2019?

Which End-use is likely to gain significant traction?

How Have advancements impacted the production procedures of this Agricultural Biotechnology in the last several years?

Purposes Behind Buying Agricultural Biotechnology Report:-

-> This report gives a stick direct examination toward changing focused elements.

-> It gives a forward-looking perspective on changed elements producing or restricting business sector improvement.

-> It gives a five-year evaluation surveyed based on how the market is anticipated to develop.

-> It helps in understanding the essential part sections and their prospect.

-> It gives stick point investigation of changing competition components and keeps you in front of contenders.

-> It helps in settling on educated business decisions by having complete bits of knowledge of the market and by making a top to bottom investigation of market fragments.

The Agricultural Biotechnology Market report concludes with sharing vital report findings with readers. Here on the basis of the study of historical data, the examination of the current scenarios overserved in various markets including regional and domestic and trends recorded, it delivers a forecast of the market. This includes segmental forecast, market size forecast, regional market forecast, consumption forecast.

Why Pick Marketresearch.biz?

Systematic Market research procedure

Data Gathered from credible and dependable secondary and primary resources

Team Of highly trained and skilled analysts with a profound comprehension of the most recent market research methods

Swift and efficient ordering process

Round the clock customer support catering to inquiries from global and domestic Customers

TO Download Detailed TOC ofAgricultural Biotechnology Market@https://marketresearch.biz/report/agricultural-biotechnology-market/#toc

Contact Us At

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300, New York City, NY 10170, United States

Tel: +1 347 826 1876

Thanks a million for reading! You can also request custom information like chapter-wise or specific region-wise study as per your interest.

See the original post here:
Inclusive comprehension of Agricultural Biotechnology Market Addressing Structure, Scope, Potential, and Growth Prospects Till 2029 - TheLoop21

Read More...

Look Vir Biotechnology (VIR) Stock Where Its Heading? – News Welcome

Saturday, February 8th, 2020

Vir Biotechnology (VIR) Stock Volatility Indicators To Watch:

Volatility of the Vir Biotechnology remained at 23.33% over last week and shows 11.80% volatility in last month. In addition to number of shares traded in last few trading sessions volatility also tells about the fluctuation level of the stock price, commonly a high volatility is the friend of day traders. Volatility is also measured by ATR an exponential moving average (14-days) of the True Ranges. Currently, the ATR value of companys stock is situated at 2.71.

Vir Biotechnology (VIR) has a market capitalization of $2.21B. Knowing about the market capitalization of a company helps investor to determine the company size, market value and the risk. The stock declined -14.36% to value at $22.81 on Monday trading session. VIR recorded volume of 1199133 shares in most recent trading session as compared to an average volume of 268.65K shares. It shows that the shares were traded in the recent trading session and traders shown interest in VIR stock. The stock EPS is $-1.26 against its recent stock value of $22.81 per share.

Looking into the Profitability indicators on Vir Biotechnology stock we analyze the stocks Profitability ratios.

Profitability Spotlight for Vir Biotechnology:

Return on Investment (ROI) of stock is 66.00%. ROI ratio tells about the efficiency of a number of investments in a company.

The price-to-earnings ratio or P/E is one of the most widely-used stock analysis tools to determine a stocks valuation

Analysts Estimation on Stock:

The current analyst consensus rating stood at 2.2 on shares (where according to data provided by FINVIZ, 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell, 5.0 Strong Sell). Analysts opinion is also an important factor to conclude a stocks trend. Many individual analysts and firms give their ratings on a stock. While Looking ahead of 52-week period, the mean Target Price set by analysts is $26.

Now entering into the performance part of the article on Vir Biotechnology stock we should check the stocks actual performance in the past.

Performance of the VIR Stock:

Vir Biotechnology revealed performance of -7.95% during the period of last 5 trading days. The stock maintained for the month at 87.70%. The stock noted year to date 2019 performance at 81.35% and changed about 61.74% over the last three months. The stock is now standing at -21.36% from 52 week-high and is situated at 95.74% above from 52-week low price.

Technical Indicators of Vir Biotechnology Stock:

RSI momentum oscillator is the most common technical indicator of a stock to determine about the momentum of the shares price and whether the stock trading at normal range or its becoming oversold or overbought. It also helps to measure Speed and change of stock price movement. RSI reading varies between 0 and 100. Commonly when RSI goes below 30 then stock is oversold and stock is overbought when it goes above 70. So as currently the Relative Strength Index (RSI-14) reading of Vir Biotechnology stock is 63.39.

Although it is important to look for trades in a direction of bigger trends when stocks are indicating an opposite short-term movement. Like looking for overbought conditions when bigger trend remained down and oversold conditions when bigger trend is up. In order to check a bigger trend for VIR a 14-day RSI can fell short and considered as a short-term indicator. So in that situation a Simple moving average of a stock can also be an important element to look in addition to RSI.

The share price of VIR is currently up 34.32% from its 20 days moving average and trading 58.72% up the 50 days moving average. The stock price has been seen performing along above drift from its 200 days moving average with 59.36%. Moving averages are an important analytical tool used to identify current price trends and the potential for a change in an established trend. The simplest form of using a simple moving average in analysis is using it to quickly identify if a security is in an uptrend or downtrend.

Read the original here:
Look Vir Biotechnology (VIR) Stock Where Its Heading? - News Welcome

Read More...

The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs – Benzinga

Saturday, February 8th, 2020

The following is a roundup of top developments in the biotech space over the last 24 hours:

(Biotech stocks that hit 52-week highsFeb. 5.)

(Biotech stocks that hit 52-week lows Feb. 5.)

See also: The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus

Sanofi SA (NASDAQ: SNY) said a Phase 2b study that evaluated its investigational BTK inhibitor SAR442168 for multiple sclerosis met the primary endpoint, with the candidate significantly reducing disease activity associated with multiple sclerosis. The candidate was also found to be safe and well-tolerated.

Separately, the company released financial results thatshowed 6.8% net sales growth for the fourth quarter, driven by Dupixent and vaccines, and 253.5% net income growth. The company said it expects 2020 business EPS to grow 5% at constant currency.

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) said it has decided to stop enrollment in the Phase 3 study dubbed RECOVERY that evaluated its Tonmya 5.6mg in treating post-traumatic stress disorder, following interim analysis of data by the Independent Data Monitoring Committee.

The IDMC sought stoppage of the trial for futility as it believed the experimental drug is unlikely to demonstrate a significant improvement in the primary endpoint of overall change from baseline in the severity of PTSD symptoms between the treatment and control arm.

The shares were plunging 59.91% to 68cents in premarket trading Thursday.

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) announced positive interim results from ongoing Phase 1/2a studies of its two RNAi-based cardiometabolic candidates: ARO-APOC3, which is being evaluated for severe hypertriglyceridemia, and ARO-ANG3, whichbeing evaluated for dyslipidemias and metabolic diseases.

The company also released fourth-quarter results, showing a sales decline of 15% to $29.46 million and a loss of 3 cents. Analysts estimated a loss of 1 cent per share for the quarter.

The stock was trading 7.5% higher to $47 in Thursday's premarket session.

Misonix Inc (NASDAQ: MSON) reported 17.3% revenue growth on a pro forma basis for its fiscal year second quarter, and its net loss widened year-over-year. The company reiterated its fiscal year 2020 outlook for revenue growth in excess of 20% and gross margins of about 70%.

The stock rose 5.97% to $19 in after-hours trading.

Cardiovascular Systems Inc (NASDAQ: CSII) reported a wider-than-expected seond-quarter loss, while revenueclimbed 13.5%. The company raised the low end of its 2020 revenue guidance.

The stock shed 1.94% to $44 in after-hours trading.

Applied Genetic Technologies Corp (NASDAQ: AGTC) said it has commenced an underwritten public offering of 6 million shares of its common stock. All the shares are being offered by the company.

The stock slipped 9.70% to $6.33 in after-hours trading.

Jounce Therapeutics Inc (NASDAQ: JNCE) will present at the ASCO-SITC Symposium Phase 1/2 data for vopratelimab, codenamed JTX-2011, in solid tumors.

Beam Therapeutics said it has priced its upsized initial public offeringof 10.59 million shares at $17 per share, at the upper end of the estimated price range of $15-$17. The shares of the company, which is engaged in developing therapies based on single-base gene editing, will begin trading on the Nasdaq under the ticker symbol "BEAM."

Contract research organization PPD priced its 60-million share IPO at $27 compared to the initially estimated range of $24-$27. The shares are to be listed on the Nasdaq under the ticker symbol "PPD."

Related Link: Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates

2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

More here:
The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs - Benzinga

Read More...

Is GeneReach Biotechnology Corp. (GTSM:4171) Investing Effectively In Its Business? – Simply Wall St

Thursday, January 30th, 2020

Today well evaluate GeneReach Biotechnology Corp. (GTSM:4171) to determine whether it could have potential as an investment idea. To be precise, well consider its Return On Capital Employed (ROCE), as that will inform our view of the quality of the business.

First of all, well work out how to calculate ROCE. Second, well look at its ROCE compared to similar companies. Then well determine how its current liabilities are affecting its ROCE.

ROCE measures the return (pre-tax profit) a company generates from capital employed in its business. In general, businesses with a higher ROCE are usually better quality. Overall, it is a valuable metric that has its flaws. Renowned investment researcher Michael Mauboussin has suggested that a high ROCE can indicate that one dollar invested in the company generates value of more than one dollar.

Analysts use this formula to calculate return on capital employed:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) (Total Assets Current Liabilities)

Or for GeneReach Biotechnology:

0.11 = NT$72m (NT$713m NT$61m) (Based on the trailing twelve months to September 2019.)

Therefore, GeneReach Biotechnology has an ROCE of 11%.

View our latest analysis for GeneReach Biotechnology

One way to assess ROCE is to compare similar companies. Using our data, GeneReach Biotechnologys ROCE appears to be around the 9.5% average of the Medical Equipment industry. Regardless of where GeneReach Biotechnology sits next to its industry, its ROCE in absolute terms appears satisfactory, and this company could be worth a closer look.

GeneReach Biotechnology has an ROCE of 11%, but it didnt have an ROCE 3 years ago, since it was unprofitable. That implies the business has been improving. The image below shows how GeneReach Biotechnologys ROCE compares to its industry, and you can click it to see more detail on its past growth.

When considering this metric, keep in mind that it is backwards looking, and not necessarily predictive. ROCE can be misleading for companies in cyclical industries, with returns looking impressive during the boom times, but very weak during the busts. ROCE is only a point-in-time measure. Since the future is so important for investors, you should check out our free report on analyst forecasts for GeneReach Biotechnology.

Current liabilities are short term bills and invoices that need to be paid in 12 months or less. Due to the way the ROCE equation works, having large bills due in the near term can make it look as though a company has less capital employed, and thus a higher ROCE than usual. To counteract this, we check if a company has high current liabilities, relative to its total assets.

GeneReach Biotechnology has total assets of NT$713m and current liabilities of NT$61m. As a result, its current liabilities are equal to approximately 8.6% of its total assets. With low current liabilities, GeneReach Biotechnologys decent ROCE looks that much more respectable.

This is good to see, and while better prospects may exist, GeneReach Biotechnology seems worth researching further. GeneReach Biotechnology shapes up well under this analysis, but it is far from the only business delivering excellent numbers . You might also want to check this free collection of companies delivering excellent earnings growth.

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

See more here:
Is GeneReach Biotechnology Corp. (GTSM:4171) Investing Effectively In Its Business? - Simply Wall St

Read More...

Is Oncolytics Biotech, Inc. (ONCY) a Winner or a Loser in the Biotechnology Industry – InvestorsObserver

Thursday, January 30th, 2020

Oncolytics Biotech, Inc. (ONCY) is near the top in its industry group according to InvestorsObserver. ONCY gets an overall rating of 78. That means it scores higher than 78 percent of stocks. Oncolytics Biotech, Inc. gets a 94 rank in the Biotechnology industry. Biotechnology is number 55 out of 148 industries.

Click Here to get the full Stock Score Report on Oncolytics Biotech, Inc. (ONCY) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Oncolytics Biotech, Inc. (ONCY) stock is trading at $3.11 as of 9:57 AM on Monday, Jan 27, a loss of -$0.16, or -5.05% from the previous closing price of $3.27. The stock has traded between $3.00 and $3.35 so far today. Volume today is below average. So far 349,770 shares have traded compared to average volume of 2,557,054 shares.

To see InvestorsObserver's Sentiment Score for Oncolytics Biotech, Inc. click here.

See the article here:
Is Oncolytics Biotech, Inc. (ONCY) a Winner or a Loser in the Biotechnology Industry - InvestorsObserver

Read More...

A case of wholehearted biotechnology adoption – The Hindu

Thursday, January 30th, 2020

In the Editorial page article, The flawed spin to Indias cotton story (January 23, 2020), there are unfounded claims about a technology that has in reality been a boon to farmers across the world.

The first point made in the article is that GM cotton covers 95% of the area under cotton and that there are no choices for farmers. The fact: Indian farmers have voted for choice of seeds with biotechnologies by planting hybrid cotton biotech seeds on over 90% of the countrys cotton acreage. They want seeds and technologies that provide optimal yield, income and convenience in cultivation. Today, they choose from over 800 hybrid Bt cotton seed brands from over 40 Indian and global seed companies, with five approved in-the-seed insect protection Bt cotton technologies and non-Bt varietal cotton seeds. Farmers have not shown any preference for planting non-Bt cotton seeds including the quantity supplied along with the Bt cotton seed by seed companies as per regulatory guidelines.

Several key studies by third-party economists and sociologists have established that 85% of hybrid Bt cotton seed farmers and farm labourers invested in better education for children; 77% reported better intake of nutritious food; 75% reported better health of their family members; 64% invested on the health of livestock; female workers on Bt cotton fields earned an average 55% higher income; and 42.4 crore additional days of rural employment have been generated, thereby doubling cotton production.

Indias farmers are the ones who have reposed trust in biotechnology, making India the worlds second largest cotton producer and exporter by doubling cotton production over the past decade.

Cotton Corporation of India data show that the highest production of 398 lakh bales of cotton in India was achieved in 2013-14, valued at around 72,000 crore. Additional incomes were generated from cotton seeds oil (1.3 million tons) and cotton seed oilmeal (11 million tons) worth 13,000 crore and 22,000 crore, respectively. The Bt cotton seed market is about 3,000 crore, making it hardly 2.5% of the total value generated.

The articles second point is about low productivity as compared to the global scene. The fact is that technology has not only increased yields but also greatly reduced pesticide use. Biotechnology in cotton, post its introduction in 2002, has led to transformational changes in Indias cotton cultivation. These have helped increase cotton yields by over 1.8 times from 241 kg/hectare in 2002-2003 to 541 kg/hectare in 2018-2019. A BKS-CSD study shows that the significant increase in farmer incomes from higher yields and reduced pesticide use has generated additional farm income of over 42,300 crore. India is moving to first place as the largest producer of cotton in the world.

However, it is not just the technology that increases yields. Indias farmers face numerous uncertainties and crop management challenges, affecting farm yield and incomes; knowledge of cultivation and correct agronomic practices can make a significant impact. This is being addressed by numerous extension efforts.

There is an opportunity to increase yields further in India when compared to other countries that have been using even more advanced GM traits than what is being used in India. New technology introduction has stopped in India since 2005, affecting growth of yields.

The articles third point is about the availability of low cost manual labour. The fact is that one of the major challenges lies in securing labour to conduct field operations. Today, labour accounts for over 58% of a farmers cost of cultivation per acre. In a fast-evolving global market, Indias farmers instead need the best technologies to remain competitive.

The next claim is about varieties offering farmers increased benefits than hybrid cotton seeds. The fact is that Indian farmers who were using varieties for years switched to hybrids in the mid-1980s mainly because of the enormous benefits. Cotton Advisory Board data show that Indias cotton yields which were at 169 kg/hectare in 1980-81 increased to 278 kg/hectare in 2000-01 and then 542 kg/ hectare in 2016-17.

The writers argument that High Density Planting (HDP) took place in various countries after introduction of biotech cotton is inaccurate. Planting rates are determined by several agronomic and environmental conditions and not based on biotech versus non-biotech. There is also no change in the seed rate in any of the countries in which biotech cotton has been adopted. HDP has done well in India because of the better quality of germplasm.

Also, Turkey is not a large cotton producer. USDA statistics in 2017-18 shows that India leads with 35m bales, followed by China (28m bales), the U.S. (21m bales), Brazil (9m bales) and Australia (5m bales). All of them are GM cotton countries, contributing to more than 90% of global cotton production. GM cotton was introduced in Brazil in 2006-07.

India also produces hybrid cotton seed because of the availability of labour to carry out the hand pollination at reasonable cost; this is not available in the U.S., Brazil, Australia and China. Hybrid cotton has delivered not only higher yields but also provided resistance to some pests and diseases.

The article also claims that Indian farmers need to buy seeds repeatedly. The fact is that not just biotech cotton, but all hybrid seeds lose their benefits if replanted, creating reduced and erratic yields. New seeds help farmers sustain high yields year on year.

In the case of biotech cotton in India, it is the farmers who adopted the technology wholeheartedly because they saw a solution in it to some of their biggest on-field pest challenges. The choice made by the Indian farmer to plant hybrid cotton seeds on over 90% of cotton acreage, and see increased cotton production is testament to the value created by better seeds, technologies and farming practices when compared with the alternative of low tech seed and insecticide sprays.

Bt cotton was released in varieties by some public institutions but it did not get much traction. There is always a debate about the use of hybrids versus varieties in any crop. The writer appears to be giving too much power to the seed industry in terms of influencing the farmer to prefer hybrids over varieties. This has not happened in the case of rice, mustard, many oilseeds, and pulses in which the farmers grow varietal crops in 90-100% of the area. The lesson is that the farmer adopts technologies which are beneficial to him and does not go by the recommendations of the industry or any other persons.

Seeds with biotechnologies have helped conserve biodiversity: with higher production from the same area, the expansion of agricultural land into forest areas has been slowed.

A one-sided depiction not only harms agriculture and the industry but also spreads misconceptions about biotechnology.

Ram Kaundinya is Director General, Federation of Seed Industry of India (FSII), New Delhi

You have reached your limit for free articles this month.

Register to The Hindu for free and get unlimited access for 30 days.

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Enjoy reading as many articles as you wish without any limitations.

A select list of articles that match your interests and tastes.

Move smoothly between articles as our pages load instantly.

A one-stop-shop for seeing the latest updates, and managing your preferences.

We brief you on the latest and most important developments, three times a day.

Not convinced? Know why you should pay for news.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

Go here to read the rest:
A case of wholehearted biotechnology adoption - The Hindu

Read More...

Vir Biotechnology, Inc. (VIR) distance from 20-day Simple moving Average is 47.94% : What to Expect? – The InvestChronicle

Thursday, January 30th, 2020

Vir Biotechnology, Inc. (VIR) is priced at $22.47 after the most recent trading session. At the very opening of the session, the stock price was $20.63 and reached a high price of $26.29, prior to closing the session it reached the value of $21.31. The stock touched a low price of $20.21.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Vir Biotechnology, Inc. shares are logging -18.22% during the 52-week period from high price, and 92.87% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $11.65 and $27.48.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 2.14 million for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Vir Biotechnology, Inc. (VIR) recorded performance in the market was 78.69%, having the revenues showcasing 48.32% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 2.19B, as it employees total of 217 workers.

Raw Stochastic average of Vir Biotechnology, Inc. in the period of last 50 days is set at 68.37%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 67.66%. In the last 20 days, the companys Stochastic %K was 70.12% and its Stochastic %D was recorded 78.51%.

Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 78.69%. The shares increased approximately by 1.27% in the 7-day charts and went down by 35.85% in the period of the last 30 days. Common stock shares were driven by 48.32% during last recorded quarter.

Read more here:
Vir Biotechnology, Inc. (VIR) distance from 20-day Simple moving Average is 47.94% : What to Expect? - The InvestChronicle

Read More...

GIOSTAR Announces Medical Breakthrough in Biotechnology and Lifesciences To Manufacture Abundant, Safe Red Blood Cells From Stem Cells – Benzinga

Thursday, January 30th, 2020

GIOSTAR/HEAMGEN has developed and secured patented technology to manufacture lifesaving mature red blood cells from stem cells. The red blood cells are made utilizing a bioreactor that permits the production of mature red blood cells, under strictly controlled conditions, for transfusion therapy and replaces the need for a human blood donor. GIOSTAR/HEAMGEN mature red blood cells are safe and not compromised by inadequate pathogen detection and inactivation of diseases such as hepatitis C, HIV, hepatitis B and syphilis. The red blood cells are O-Negative (Universal Donor) to eliminate incompatibility and allosensitization reactions.

ATLANTA (PRWEB) January 29, 2020

GIOSTAR/HEAMGEN has developed and secured patented technology to manufacture lifesaving mature red blood cells from stem cells. The red blood cells are made utilizing a bioreactor that permits the production of mature red blood cells, under strictly controlled conditions, for transfusion therapy and replaces the need for a human blood donor. GIOSTAR/HEAMGEN mature red blood cells are safe and not compromised by inadequate pathogen detection and inactivation of diseases such as hepatitis C, HIV, hepatitis B and syphilis. The red blood cells are O-Negative (Universal Donor) to eliminate incompatibility and allosensitization reactions. Trauma situations often do not allow for adequate blood typing due to time restrictions, so the GIOSTAR/HEAMGEN red blood cells address that need effectively.

"There are three main problems for blood transfusions," stated Dr. Anand Srivastava, Founder and Chairman of GIOSTAR. "First we have to match the blood type. Second, there's not enough blood available every single time. And third, when we transfer blood from one person to another person, there is always a chance of the transfer of disease."

Watch a feature interview with Dr. Anand Srivastava on The DM Zone with host Dianemarie Collins.

The World Health Organization (WHO) published the first detailed analysis on the global supply and demand for blood in October 2019 and found that 119 out of 195 countries do NOT have enough blood in their blood banks to meet hospital needs. In those nations, which include every country in central, eastern, and western sub-Saharan Africa, Oceania (not including Australasia), and south Asia are missing roughly 102,359,632 units of blood, according to World Health Organization (WHO) goals. While total blood supply around the world was estimated to be around 272 million units, in 2017, demand reached 303 million units. That means the world was lacking 30 million units of blood, and in the 119 countries with insufficient supply, that shortfall reached 100 million units.

The global market opportunity for GIOSTAR/HEAMGEN technology presents not only a profitable and scalable business opportunity but also a significant social and environmental impact. The global market is estimated to be at least $ 85 Billion/year.

GIOSTAR/HEAMGEN has identified early entry global markets to include Military, Trauma, Asia (replace Hepatitis C contaminated blood products), Africa (AIDS contaminated blood), Newborns, Thalassemia patients, Allosensitized sickle cell disease patients. South Sudan was found to have the lowest supply of blood, at 46 units per 100,000 people. In fact, the country's need for blood was deemed 75 times greater than its supply. In India, which had the largest absolute shortage, there was a shortfall of nearly 41 million units, with demand outstripping supply by over 400 percent. Strategic investments are needed in many low-income and middle-income countries to expand national transfusion services and blood management systems. Oncology is a major user of blood transfusion but if countries don't have the capacity to manage the bulk of oncology, it will limit complex surgery options.

GIOSTAR/HEAMGEN has acquired the exclusive license to the patent for the technique for stem cell proliferation from University of California San Diego (UCSD). The founding team of GIOSTAR/HEAMGEN is comprised of the scientists and clinicians who were involved in creating the Intellectual Property at UCSD and has already achieved PROOF OF CONCEPT - the optimized lab scale proliferation of mature red blood cells - at UCSD as part of their research.

GIOSTAR/HEAMGEN is currently looking for strategic partnerships (Contact Doug@DMProductionsLLC.com) to accelerate the development of donor-independent red blood cells manufacturing capabilities and advance the proof of concept work already done (patented) around the manufacture of safe, universal donor, human red blood cells. GIOSTAR/HEAMGEN will also develop a full automated proprietary bioreactor using robotic technology to produce abundant quantities of red blood cells with a goal for cost-effective commercialization of fresh, human, universal donor Red Blood Cells (RBCs).

ABOUT GIOSTAR

Dr. Anand Srivastava is a Chairman and Cofounder of California based Global Institute of Stem Cell Therapy and Research (GIOSTAR) headquartered in San Diego, California, (U.S.A.). The company was formed with the vision to provide stem cell based therapy to aid those suffering from degenerative or genetic diseases around the world such as Parkinson's, Alzheimer's, Autism, Diabetes, Heart Disease, Stroke, Spinal Cord Injuries, Paralysis, Blood Related Diseases, Cancer and Burns. GIOSTAR is a leader in developing most advance stem cell based technology, supported by leading scientists with the pioneering publications in the area of stem cell biology. Company's primary focus is to discover and develop a cure for human diseases with the state of the art unique stem cell based therapies and products. The Regenerative Medicine provides promise for treatments of diseases previously regarded as incurable.

GIOSTAR is world's leading Stem cell research company involved with stem cell research work for over a decade. It is headed by Dr Anand Srivastava, who is a pioneer and a world-renowned authority in the field of Stem Cell Biology, Cancer and Gene therapy. Several governments and organizations including USA, India, China, Turkey, Kuwait, Thailand, Philippines, Bahamas, Saudi Arabia and many others seek his advice and guidance on drafting their strategic and national policy formulations and program directions in the area of stem cell research, development and its regulations. Under his creative leadership, a group of esteemed scientists and clinicians have developed and established Stem Cell Therapy for various types of autoimmune diseases and blood disorders, which are being offered to patients in USA and soon it will be offered on a regular clinical basis to the people around the globe.

For the original version on PRWeb visit: https://www.prweb.com/releases/giostar_announces_medical_breakthrough_in_biotechnology_and_lifesciences_to_manufacture_abundant_safe_red_blood_cells_from_stem_cells/prweb16854975.htm

Read more here:
GIOSTAR Announces Medical Breakthrough in Biotechnology and Lifesciences To Manufacture Abundant, Safe Red Blood Cells From Stem Cells - Benzinga

Read More...

Changed landscape of biotech sector, fiercely committed to India, says Department of Biotechnology secretary Dr Renu Swarup – The Indian Express

Thursday, January 30th, 2020

Written by Anuradha Mascarenhas | Pune | Published: January 29, 2020 5:20:12 am Dr M K Bhan

Hailing him as the strong pillar on which the Department of Biotechnology (DBT) stood today, secretary Dr Renu Swarup said noted paediatrician and former DBT secretary Dr M K Bhan, who died on January 26, changed the landscape of the biotechnology sector and was among those scientists who had been able to fulfil the dream of introducing a rotavirus vaccine, now part of the universal immunisation programme. Swarup worked closely with Dr Bhan for over a decade.

Dr Bhan pioneered the first indigenously developed rotavirus vaccine and the highest tribute to him would be to take forward his legacy, Dr Swarup said, adding that he was a visionary and his death had left a void that will never get filled.

The rotavirus vaccine was developed from scratch and the government introduced it in the public health programme from 2016.

Generous and passionate about building up young people, Dr Bhan was fiercely committed to our country and its science, but gentle in his approach to individuals and rigorous in his approach to institutions. Dr Bhan was unique and special, Prof Gagandeep Kang, executive director of Translational Health Science and Technology Institute, Faridabad, told The Indian Express.

Prof Chittaranjan Yajnik, noted diabetologist and director of the diabetes unit at KEM hospital in Pune said his death was a massive loss to Indian science. His legacy will guide us in solving problems, said Prof Yajnik, who was his close friend.

Prof Yajnik added that he was a visionary scientist who handled science, its translation and management seamlessly. Dr Bhan was instrumental in promoting new biotechnology institutes in different parts of the country and involving scientists of multiple specialties to interact with each other under the umbrella of biotechnology.

We are now observing the fruits of this approach. He was instrumental in setting up the vaccine field trial unit at KEM hospital, which has contributed significantly to rotavirus research and related studies, Prof Yajnik said.

Dr Bhan was my mentor; as a young trainee gastroenterologist visiting AIIMS, he inspired us to inculcate a systematic approach to clinical problems and as a teacher of epidemiology he shared his belief that public health research was the need of the hour, said Dr Ashish Bawdekar, consultant paediatric gastroenterologist at KEM hospital.

Dr Bawdekar further talked of his close involvement with Dr Bhan, who was the DBT secretary during the development of the Indian rotavirus vaccine.

He was extremely nationalistic and felt Indian scientists were as good as others in the world and would not accept any interference from foreign funders. It was unbelievable what he could foresee and then, more importantly, do something about it, he said.

Dr Sanjay Juvekar, head of the Vadu Rural Health Programme said their team will cherish the experience shared with Dr Bhan on the rotavirus vaccine research,

He was in favour of translational research that could yield results with immediate benefits to the public. Apart from his immense contribution towards the indigenous rotavirus vaccine, he was also instrumental in the identification of zinc deficiency as the cause behind several abnormalities observed in children, said Dr Manoj Kumar Bhat, director of National Centre for Cell Science (NCCS).

Senior scientist at NCCS, Dr Yogesh Shouche, said during his tenure, Dr Bhan came up with several new initiatives not only in health but also in other sectors like agriculture and food processing.

For all the latest Pune News, download Indian Express App

Read the rest here:
Changed landscape of biotech sector, fiercely committed to India, says Department of Biotechnology secretary Dr Renu Swarup - The Indian Express

Read More...

B.R.A.I.N. Biotechnology Research and Information Network AG Just Released Its Full-Year Results And Analysts Are Updating Their Estimates – Yahoo…

Saturday, January 18th, 2020

B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) just released its yearly report and things are looking bullish. Results overall were solid, with revenues arriving 9.7% better than analyst forecasts at 40m. Higher revenues also resulted in substantially lower statutory losses which, at 0.58 per share, were 9.7% smaller than analysts expected. This is an important time for investors, as they can track a company's performance in its report, look at what top analysts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what analysts' statutory forecasts suggest is in store for next year.

Check out our latest analysis for B.R.A.I.N. Biotechnology Research and Information Network

XTRA:BNN Past and Future Earnings, January 18th 2020

Following the latest results, B.R.A.I.N. Biotechnology Research and Information Network's four analysts are now forecasting revenues of 43.5m in 2020. This would be a solid 8.6% improvement in sales compared to the last 12 months. Per-share statutory losses are expected to see a sharp uptick, reaching 0.47. Before this earnings announcement, analysts had been forecasting revenues of 40.0m and losses of 0.29 per share in 2020. While next year's revenue estimates increased, there was also a large cut to EPS expectations, suggesting the consensus has a bit of a mixed view of these results.

There was no major change to the consensus price target of 17.80, with growing revenues seemingly enough to offset the concern of growing losses. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on B.R.A.I.N. Biotechnology Research and Information Network, with the most bullish analyst valuing it at 24.00 and the most bearish at 9.50 per share. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.

Zooming out to look at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up both against past performance, and against industry growth estimates. We would highlight that B.R.A.I.N. Biotechnology Research and Information Network's revenue growth is expected to slow, with forecast 8.6% increase next year well below the historical 15%p.a. growth over the last five years. By way of comparison, other companies in this market with analyst coverage, are forecast to grow their revenue at 3.8% next year. So it's pretty clear that, while B.R.A.I.N. Biotechnology Research and Information Network's revenue growth is expected to slow, it's still expected to grow faster than the market itself.

Pleasantly, analysts also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider market. The consensus price target held steady at 17.80, with the latest estimates not enough to have an impact on analysts' estimated valuations.

Still, the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for B.R.A.I.N. Biotechnology Research and Information Network going out to 2024, and you can see them free on our platform here.

Story continues

Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Read the original post:
B.R.A.I.N. Biotechnology Research and Information Network AG Just Released Its Full-Year Results And Analysts Are Updating Their Estimates - Yahoo...

Read More...

Page 35«..1020..34353637..4050..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick